Tandem Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Tandem Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,480	Closed	-$221K	–	116
2023 Q4	$221K	Sell	2,480 -460	-16%	-$34.2K	0.14%	106
2023 Q3	$215K	Sell	2,940 -460	-14%	-$36.7K	0.15%	104
2023 Q2	$283K	Hold	3,400	–	–	0.18%	97
2023 Q1	$259K	Sell	3,400 -940	-22%	-$78K	0.18%	93
2022 Q4	$360K	Sell	4,340 -4,465	-51%	-$361K	0.28%	72
2022 Q3	$694K	Buy	8,805 +210	+2%	+$17.7K	0.59%	52
2022 Q2	$638K	Buy	8,595 +270	+3%	+$20.3K	0.51%	52
2022 Q1	$679K	Buy	8,325 +2,270	+37%	+$210K	0.47%	56
2021 Q4	$678K	Buy	+6,055	New	+$730K	0.39%	58

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tandem Capital Management's XBI Position: Q1 2024 in Review

Tandem Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 2,480 shares — an estimated $221K sold.

Tandem Capital Management first reported a position in XBI in Q4 2021 and held it in 9 quarters. The position peaked at $694K in Q3 2022. 780 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Tandem Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Tandem Capital Management sold 2,480 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $221K.
Tandem Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 9 quarters.
Tandem Capital Management's State Street SPDR S&P Biotech ETF position peaked at $694K in Q3 2022.
780 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Tandem Capital Management's 13F filing for Q1 2024, filed 16 May 2024.